RxDoctor Payments Data

Jenae Reece

Family · Reno, NVNPI 1700568151

Payments from drug & device makers

$681in general payments, 2019–2025

Across 26 payments — averaging $26.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$239
  • Gilead$122
  • Amgen$56
  • Lilly USA, LLC$47
  • Boehringer Ingelheim$41
  • Novo Nordisk$35
  • plus $141 from 5 others

What the payments were for

  • Food & beverage$681100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie10$239
Gilead1$122
Amgen(2 entities)2$56
Lilly USA, LLC2$47
Boehringer Ingelheim2$41
Novo Nordisk2$35
Pfizer2$33
Sanofi Pasteur Inc.1$32
Merck2$30
Vertex1$27
Seqirus USA Inc1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$681 in reported general payments places this provider in the 60th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$355
Medicare patients
18
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$38,859
EliquisApixaban19$19,265
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$858
Atorvastatin Calcium64$720
Albuterol Sulfate HfaAlbuterol Sulfate33$682
Fluphenazine Hcl11$632
Rosuvastatin Calcium26$480
Duloxetine Hcl13$327
Omeprazole20$263
Gabapentin26$246
Lisinopril39$244
Levothyroxine Sodium27$224
Metformin Hcl23$199
Hydroxyzine Hcl15$193
Pantoprazole Sodium20$183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$35$38,85933 claims
PfizerEliquis$33$19,26519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,501 family providers in Nevada.

Other family in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →